Putting the Risk of Breast Cancer in Perspective

Princess Margaret Hospital, Toronto, ON, Canada.
New England Journal of Medicine (Impact Factor: 55.87). 02/1999; 340(2):141-4. DOI: 10.1056/NEJM199901143400211
Source: PubMed
3 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elke maligne tumor moet toch ooit klein begonnen zijn; dus als je hem in de kiem kunt smoren, zal de patiƫnt daarmee beter af zijn. Die ogenschijnlijke vanzelfsprekendheid maakte van kankerscreening een even hardnekkige als kostbare mythe en wee degene die hem wil ontkrachten. De belofte van een lagere sterftekans vormt de legitimatie voor bevolkingsonderzoeken naar baarmoederhals- en borstkanker. Al bij de introductie van borstkankerscreening werd gewaarschuwd voor overspannen verwachtingen.1 Op grond van de uitkomsten van proefprojecten in Nederland en buitenlandse gerandomiseerde onderzoeken verwachtte men op grond van computermodellen dat door borstkankerscreening op jaarbasis te zijner tijd 700 tot 800 vrouwenlevens konden worden gespaard.
    Huisarts en wetenschap 03/2002; 45(3):697-699. DOI:10.1007/BF03083084
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of a triage system in the emergency department allows for the ability to reliably assign patients for treatment within a short amount of time in order to prioritize and treat on the basis of patients injury and illness. A 5 point triage system has been shown to have the highest correlation with effective resource utilizations, lower time to be seen and treatment times, and admission or release outcomes for patients. The problem is, however, that these triage scales were developed on the basis of physical illness and not on the ever-increasing number of patients who present with mental illness. This article compares one physical and one specific mental illness-based triage system to measure the differences in times to be seen by a physician. It found that the specialized psychiatric triage system decreased wait times and allowed symptoms to be addressed sooner for patients presenting with psychiatric complaints.
    The Journal of ambulatory care management 01/2014; 37(1):11-9. DOI:10.1097/JAC.0000000000000001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To conduct an evidence-based technology assessment to determine whether tamoxifen and raloxifene as breast cancer risk-reduction strategies are appropriate for broad-based conventional use in clinical practice. POTENTIAL INTERVENTION: Tamoxifen and raloxifene. Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefits. A comprehensive, formal literature review was conducted for tamoxifen and raloxifene on the following topics: breast cancer risk reduction; tamoxifen side effects and toxicity, including endometrial cancer risk; tamoxifen influences on nonmalignant diseases, including coronary heart disease and osteoporosis; and decision making by women at risk for breast cancer. Testimony was collected from invited experts and interested parties. More weight was given to publications that described randomized trials. BENEFITS/HARMS/COSTS: The American Society of Clinical Oncology (ASCO) Working Group acknowledges that a woman's decision regarding breast cancer risk-reduction strategies will depend on the importance and weight attributed to the information provided regarding both cancer and non-cancer-related risks. For women with a defined 5-year projected risk of breast cancer of >/= 1.66%, tamoxifen (at 20 mg/d for up to 5 years) may be offered to reduce their risk. It is premature to recommend raloxifene use to lower the risk of developing breast cancer outside of a clinical trial setting. On the basis of available information, use of raloxifene should currently be reserved for its approved indication to prevent bone loss in postmenopausal women. Conclusions are based on single-agent use of the drugs. At the present time, the effect of using tamoxifen or raloxifene with other medications (such as hormone replacement therapy), or using tamoxifen and raloxifene in combination or sequentially, has not been studied adequately. The continuing use of placebo-controlled trials in other risk-reduction trials highlights the current unanswered issues concerning the use of such interventions, especially when the influence on net health benefit remains to be determined. Breast cancer risk reduction is a rapidly evolving area. This technology assessment represents an ongoing process with existing plans to monitor and review data and to update recommendations in a timely matter. (See The conclusions of the Working Group were evaluated by the ASCO Health Services Research Committee and by the ASCO Board of Directors. American Society of Clinical Oncology.
    Journal of Clinical Oncology 06/1999; 17(6):1939-55. · 18.43 Impact Factor
Show more

Similar Publications